We are live on ! Find out more
ONC icon

BeOne Medicines

205 hedge funds and large institutions have $7.3B invested in BeOne Medicines in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 90 increasing their positions, 45 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more capital inflows, than outflows

Capital inflows: $475M | Capital outflows: $212M

100% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 45

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

1.32% more ownership

Funds ownership: 43.18% → 44.5% (+1.3%)

9% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 35

8% more call options, than puts

Call options by funds: $14.2M | Put options by funds: $13.2M

0% more funds holding

Funds holding: 204 → 205 (+1)

Holders
205
Holders Change
+1
Holders Change %
+0.49%
% of All Funds
2.94%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.14%
New
38
Increased
90
Reduced
45
Closed
35
Calls
$14.2​M
Puts
$13.2​M
Net Calls
+$1.03​M
Net Calls Change
+$365​K

ONC Hedge Fund Activity: Q1 2024 in Review

205 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q1 2024, worth a combined $7.3B — down 10% from $8.11B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ONC positions and 35 closed out — a net gain of 3 holders — while 90 added to existing stakes and 45 trimmed.

The largest buyer was Capital International Investors, adding an estimated $117M. The largest seller was Invesco, cutting an estimated $43.4M.

  • 205 institutional investors held BeOne Medicines (ONC) as of Q1 2024, up from 204 in Q4 2023.
  • Funds reported $7.3B of BeOne Medicines stock for Q1 2024, down 10% quarter-over-quarter.
  • 38 funds opened new BeOne Medicines positions in Q1 2024 and 35 closed out, a net change of +3 holders.
  • The largest BeOne Medicines buyer in Q1 2024 was Capital International Investors, an estimated $117M added.
  • The largest BeOne Medicines seller in Q1 2024 was Invesco, an estimated $43.4M sold.

Based on aggregated 13F filings for Q1 2024.